BEST-J score 17+

Yoichi Kakuta

Progettata per iPhone

    • Gratis

Screenshot iPhone

Descrizione

Bleeding after ESD occurs in 4.1%–8.5% of patients who undergo gastric ESD. The "BEST-J score" is a prediction model to stratify the risk of bleeding after ESD for early gastric cancers. Nine factors were weighted with point values: 4 points for anticoagulants (warfarin, direct oral anticoagulants), 3 points for chronic kidney disease with hemodialysis, 2 points each for P2Y12 receptor antagonist (thienopyridine) and aspirin, 1 point each for cilostazol, a tumor size >30 mm, lower-third in tumor location, and presence of multiple tumors, and −1 point for interruption of each kind of antithrombotic agents. The patients were categorized into four bleeding risk groups: low (0–1 points: 2.8% risk), intermediate (2 points: 6.1%), high (3–4 points: 11.4%) and very high (≥5 points: 29.7%).

*1. If an antiplatelet agent was replaced with another agent, select "Temporal discontinuation" of the original agent and "None" of the replaced agent. For example, if P2Y12 receptor antagonist is replaced with aspirin, select "Temporal discontinuation" of P2Y12 receptor antagonist and "None" of aspirin.

*2. If the patient received heparin bridging therapy, select "Temporal discontinuation" of the original agent. For example, if warfarin is bridged with heparin, select "Temporal discontinuation" of warfarin.

*3. Time of discontinuing antithrombotic agents before ESD is based on the Japanese guidelines (Dig Endosc. 2014; 26: 1-14.): aspirin, 3−5 days; P2Y12 receptor antagonist (thienopyridine), 5−7 days; cilostazol, 1 day; warfarin, 3−5 days; DOAC, 1−2 days.


For more information, see the reference below.
Gut. 2020 [Epub ahead of print]
A prediction model of bleeding after endoscopic submucosal dissection for early gastric cancer: BEST-J score.
Hatta W, Tsuji Y, Yoshio T, Kakushima N, Hoteya S, Doyama H, Nagami Y, Hikichi T, Kobayashi M, Morita Y, Sumiyoshi T, Iguchi M, Tomida H, Inoue T, Koike T, Mikami T, Hasatani K, Nishikawa J, Matsumura T, Nebiki H, Nakamatsu D, Ohnita K, Suzuki H, Ueyama H, Hayashi Y, Sugimoto M, Yamaguchi S, Michida T, Yada T, Asahina Y, Narasaka T, Kuribayashi S, Kiyotoki S, Mabe K, Nakamura T, Nakaya N, Fujishiro M, Masamune A.


You can view the application help by tapping a title bar.

DISCLAIMER: This application is intended for educational or research purposes only. It does not create any patient-physician relationship, and should not be used as a substitute for professional diagnosis and treatment.

[Developer]
2020 東北大学病院消化器内科・大腸グループ
2020 Kenichi Negoro, MD, PhD
2020 Yoichi Kakuta, MD, PhD
2020 Waku Hatta, MD, PhD (Consultant)
2020 Xiaoyi Jin, MD, PhD (Translation)
http://www.gastroente.med.tohoku.ac.jp/
tohoku.ibd@gmail.com

Privacy dell’app

Lo sviluppatore, Yoichi Kakuta, non ha fornito a Apple dettagli sulle proprie procedure per la tutela della privacy e il trattamento dei dati. Per ulteriori informazioni, consulta l’informativa sulla privacy dello sviluppatore.

Dettagli non forniti

Lo sviluppatore dovrà fornire dettagli sulla privacy quando pubblicherà il prossimo aggiornamento dell’app.

Altre app di questo sviluppatore

Geno-P
Istruzione
CHAMPS score
Salute e benessere
eCura
Salute e benessere
IBD-QR
Medicina

Ti potrebbe piacere

第107回日本消化器内視鏡学会総会
Medicina
第105回日本消化器内視鏡学会総会
Medicina
肝炎治療GL
Medicina
JPN GL 2021
Medicina
肝硬変重症度Child分類・消化器癌進行度分類
Medicina
日本胃癌学会総会
Medicina